Skip to main content

Advertisement

SpringerLink
Log in

Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in China

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Purpose

Type 2 diabetes (T2D) increases the risk of cardiovascular disease (CVD). Achieving glycated hemoglobin (HbA1c) below 7.0 % in newly diagnosed T2D reduced CVD risk. It is uncertain whether HbA1c below 7.0 % in T2D with varying duration of diabetes also reduced CVD risk. This study investigated the associations between hyperglycemia and abnormal lipid metabolism in patients with T2D.

Methods

We conducted a survey of 19,757 outpatients with T2D who were 18 years of age or more and treated with oral antidiabetes drugs (OADs) alone or OADs combined with other drugs. The coverage rates of the 3A hospitals were 74.4 % for Beijing (n = 32), 76 % for Shanghai (n = 22), 55 % for Tianjin (n = 11) and 29.3 % for Guangzhou (n = 12). Abnormal lipids were defined as ≥2.6 mmol/L for low-density lipoprotein (LDL) cholesterol, ≤1.0 mmol/L in men and ≤1.3 mmol/L in women for high-density lipoprotein (HDL) cholesterol; ≥1.7 mmol/L for triglyceride. Logistic regression stratified on city and hospital was used to obtain odds ratio (OR) of hyperglycemia for abnormal lipids.

Results

The patients had 4.0 (interquartile range 1.7–8.8) years of duration of diabetes. HbA1c ≥7.0 % was associated with increased risk of high LDL cholesterol (multivariable OR of ≥7.0 vs. <6.0 %:1.37, 95 % confidence interval 1.19–1.57). HbA1c ≥6.5 % was associated increased risk of high triglyceride. HbA1c was associated with low HDL cholesterol in a J-shaped manner, whereby HbA1c levels of <6.0 % as well as ≥6.5 % being associated with increased risk of low HDL cholesterol.

Conclusions

Hyperglycemia defined as HbA1c ≥7.0 % increased risk of high LDL cholesterol in T2D.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321

    Article  PubMed  Google Scholar 

  2. Pan XR, Yang WY, Li GW, Liu J (1997) Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care 20:1664–1669

    Article  CAS  PubMed  Google Scholar 

  3. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J et al (2010) Prevalence of diabetes among men and women in China. N Engl J Med 362:1090–1101

    Article  CAS  PubMed  Google Scholar 

  4. Xu Y, Wang L, He J, Bi Y, Li M, Wang T et al (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310:948–959

    Article  CAS  PubMed  Google Scholar 

  5. The Emerging Risk Factors Collaboration (2010) Diabetes mellitus, fasting blood glucose concentration and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lacent 26(375):2215–2222

  6. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986

    Article  Google Scholar 

  7. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653

    Article  PubMed  Google Scholar 

  8. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853

    Article  Google Scholar 

  9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589

    Article  CAS  PubMed  Google Scholar 

  10. Gaede PL-AH, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 7(358):580–591

    Article  Google Scholar 

  11. Duckworth WAC, Moritz T, Reda D, Emanuele N, Reaven PD et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 8(360):129–139

    Article  Google Scholar 

  12. Heller SR (2009) A summary of the advance trial. Diabetes Care 32(Suppl 2):S357–S361

    Article  PubMed Central  PubMed  Google Scholar 

  13. Patel AMS, Chalmers J, Neal B, Billot L, Woodward M et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 12(358):2560–2572

    Google Scholar 

  14. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q et al (2008) The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 371:1783–1789

    Article  PubMed  Google Scholar 

  15. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53:298–304

    Article  PubMed  Google Scholar 

  16. American Diabetes Association (2013) Standards of medical care in diabetes-2013. Diabetes Care 36(Suppl 1):S11–S66

    Article  PubMed Central  Google Scholar 

  17. Chehade JM, Gladysz M, Mooradian AD (2013) Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs 73:327–339

    Article  CAS  PubMed  Google Scholar 

  18. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K (2011) Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 34:145–150

    Article  PubMed Central  PubMed  Google Scholar 

  19. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502

    CAS  PubMed  Google Scholar 

  20. American Diabetes Association (2013) Executive summary: standards of medical care in diabetes-2013. Diabetes Care 36(Suppl 1):s4–s10

    Google Scholar 

  21. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853

    Article  Google Scholar 

  22. Weng J, Yang X (2013) Unsubstantiated concerns over the safety of use of sulphonylureas and insulin for increased risk of diabetes complications. J Diabetes 6:30–32

    Article  PubMed  Google Scholar 

  23. Yang X, So WY, Ma R, Ko G, Kong A, Lam C et al (2008) Effects of albuminuria and renal dysfunction on development of dyslipidaemia in type 2 diabetes–the Hong Kong Diabetes Registry. Nephrol Dial Transplant 23:2834–2840

    Article  CAS  PubMed  Google Scholar 

  24. Yang X, Ma RC, So WY, Ko GT, Kong AP, Lam CW et al (2007) Impacts of chronic kidney disease and albuminuria on associations between coronary heart disease and its traditional risk factors in type 2 diabetic patients: the Hong Kong diabetes registry. Cardiovasc Diabetol 6:37

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Yang X, Ko GT, So WY, Ma RC, Kong AP, Lam CW et al (2008) Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes Registry. Diabetes Care 31:2294–2300

    Article  PubMed Central  PubMed  Google Scholar 

  26. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645

    Article  CAS  PubMed  Google Scholar 

  27. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL (1999) Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 96:13656–13661

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Han R, Lai R, Ding Q, Wang Z, Luo X, Zhang Y et al (2007) Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50:1960–1968

    Article  CAS  PubMed  Google Scholar 

  29. Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC (2012) Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings–what, why and how? Diabetes Obes Metab 14:579–585

    Article  CAS  PubMed  Google Scholar 

  30. Yang X, So WY, Ma RC, Ko GT, Kong AP, Wang Q et al (2008) Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer 15:597–607

    Article  CAS  PubMed  Google Scholar 

  31. Yang W, Zhao W, Xiao J, Li R, Zhang P, Kissimova-Skarbek K et al (2012) Medical care and payment for diabetes in China: enormous threat and great opportunity. PLoS ONE 7:e39513

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a research grant from Novo Nordisk, China.

Conflict of interest

The authors have declared no financial relationship relevant to this article except that the authors other than X.Y. are investigators of this project, which was supported by a grant from Novo Nordisk, China.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Peking University People’s Hospital, Xicheng District, Beijing, China

    Linong Ji

  2. Department of Endocrinology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    Jianping Weng

  3. Department of Endocrinology, Chinese PLA General Hospital, Beijing, China

    Juming Lu

  4. Department of Endocrinology, First Hospital of Peking University, Beijing, China

    Xiaohui Guo

  5. Department of Endocrinology, Sino-Japan Friendship Hospital, Beijing, China

    Wenying Yang

  6. Department of Endocrinology, Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, China

    Weiping Jia

  7. Department of Endocrinology, Changhai Hospital of Shanghai, Shanghai, China

    Dajin Zou

  8. Department of Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

    Zhiguang Zhou

  9. Department of Endocrinology, Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

    Dalong Zhu

  10. Department of Endocrinology, Xijing Hospital Affiliated to 4th Military Medical University, Xi’an, Shaanxi, China

    Qiuhe Ji

  11. Department of Endocrinology, Hospital of Guiyang Medical University, Guiyang, Guizhou, China

    Lixin Shi

  12. Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, 22 Qixiangtai Road, Heping District, P.O. Box 154, Tianjin, 300070, China

    Xilin Yang

Authors
  1. Linong Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianping Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juming Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaohui Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wenying Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weiping Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dajin Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhiguang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dalong Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Qiuhe Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lixin Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Xilin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Linong Ji or Xilin Yang.

Additional information

L. Ji and J. Weng equal contribution to the manuscript.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 138 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ji, L., Weng, J., Lu, J. et al. Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in China. J Endocrinol Invest 37, 843–852 (2014). https://doi.org/10.1007/s40618-014-0115-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-014-0115-4

Keywords

Search

Navigation